8-K: Arcadia Biosciences Raises $2.1M via Discounted Option Exercise

Arcadia Biosciences secured approximately $2.1 million in gross proceeds by inducing investors to exercise existing preferred investment options at a reduced price, issuing new options as an incentive.

Summary

• Arcadia Biosciences, Inc. (RKDA) entered into inducement offer letter agreements with certain investors on January 9, 2026.
• Participating Holders agreed to exercise 808,595 existing preferred investment options (originally issued between December 2020 and March 2023) at a reduced exercise price of $2.575 per share, down from their original $9.00 per share.
• In consideration for this exercise, the Company issued new unregistered preferred investment options to purchase up to 1,617,190 shares of common stock (200% of the shares from exercised existing options).
• The new preferred investment options have an exercise price of $2.325 per share, are immediately exercisable, and expire 30 months after the effective date of their resale registration statement.
• The Company received aggregate gross proceeds of approximately $2.1 million from the exercise of the existing options.
• H.C. Wainwright & Co., LLC acted as the exclusive placement agent, receiving a cash fee of 7.0% of gross proceeds, a 1.0% management fee, $50,000 for legal expenses, and $25,000 for non-accountable expenses.
• The Company also issued Placement Agent Options to Wainwright or its designees to purchase 56,602 shares (7.0% of the shares underlying the exercised existing options) with an exercise price of $3.2188 per share.
• Net proceeds are intended for working capital and general corporate purposes.
• The Company agreed to file a resale registration statement for the new options and placement agent options within 30 days of the closing date and use commercially reasonable efforts to have it declared effective within 60-90 days.

Sentiment

Score: 3

Explanation: The sentiment is negative due to the significant reduction in the exercise price of existing options, indicating a likely depressed stock price. The issuance of new options at 200% of the exercised shares, coupled with substantial placement agent fees, points to a high cost of capital and significant future dilution for existing shareholders. While capital was raised, the terms suggest financial distress or a challenging funding environment.

Positives

• The Company successfully raised approximately $2.1 million in gross proceeds, providing capital for working capital and general corporate purposes.
• The transaction converted existing preferred investment options into common stock, potentially simplifying the capital structure for those specific options.

Negatives

• The Company significantly reduced the exercise price of existing preferred investment options from $9.00 to $2.575 per share, indicating a substantial discount to induce exercise.
• The issuance of new preferred investment options for 1,617,190 shares (200% of the exercised shares) and additional Placement Agent Options (56,602 shares) represents significant potential future dilution for existing shareholders.
• Substantial fees and expenses were paid to the placement agent, including a 7.0% cash fee, a 1.0% management fee, and reimbursed legal and non-accountable expenses totaling $75,000.
• The Company agreed to restrictions on future equity sales for 45 days and variable rate transactions for one year, limiting financial flexibility.

Risks

• Forward-looking statements involve known and unknown risks, uncertainties, and other factors that may cause actual results to be materially different from anticipated results.
• The Company requires additional funding to continue its operations and planned activities, and there are no assurances that required funding will be available in sufficient amounts or at all.
• The new preferred investment options and placement agent options, along with their underlying shares, have not been registered under the Securities Act of 1933, imposing resale restrictions until a resale registration statement becomes effective or an exemption is available.
• Failure to file or declare effective the resale registration statement by specified dates will result in the Company paying liquidated damages to holders of new preferred investment options.
• The issuance of new options and potential exercise at lower prices could lead to significant dilution for current common stockholders.

Future Outlook

The Company intends to use the net proceeds from this offering for working capital and general corporate purposes. It also plans to file a resale registration statement for the newly issued options and placement agent options within 30 days of the closing date and aims for it to be declared effective by the SEC within 60 to 90 days. The Company has also committed to certain restrictions on future equity issuances and variable rate transactions for specified periods.

Management Comments

• Thomas J. Schaefer, Chief Executive Officer, signed the 8-K filing on behalf of Arcadia Biosciences, Inc.

Industry Context

This capital raise by Arcadia Biosciences, a producer and marketer of innovative wellness products, reflects a common strategy for smaller, growth-oriented companies in the biotechnology or specialized agriculture sectors to secure funding. The use of inducement offers with reduced exercise prices and new option issuances suggests a need for immediate capital, potentially in a challenging market environment for direct equity raises. The significant fees paid to the placement agent are typical for such transactions, especially for companies that may have limited access to broader capital markets.

Comparison to Industry Standards

• The inducement structure, involving a reduced exercise price for existing options and the issuance of new options, is often seen in companies facing liquidity challenges or seeking to strengthen their balance sheet quickly, where traditional equity raises might be difficult or highly dilutive at current market prices.
• The placement agent fees (7% cash fee, 1% management fee, plus expenses) are within the typical range for small-cap equity offerings, which can vary from 5% to 10% depending on the size and perceived risk of the offering.
• The beneficial ownership limitation (4.99% or 9.99%) is a standard provision in such agreements to prevent any single holder from immediately triggering beneficial ownership reporting requirements under Section 13(d) of the Exchange Act, which could signal a potential takeover or activist interest.

Stakeholder Impact

• **Shareholders:** Existing shareholders face significant potential dilution from the issuance of new preferred investment options (1,617,190 shares) and placement agent options (56,602 shares). The reduced exercise price for existing options also reflects a lower valuation for the company's stock.
• **Investors (Participating Holders):** These investors benefit from exercising their existing options at a significantly reduced price and receiving new options, providing them with additional upside potential at a lower cost basis.
• **Placement Agent (H.C. Wainwright & Co., LLC):** The placement agent received substantial fees and additional options, indicating a favorable outcome for their services.
• **Company:** The Company gains approximately $2.1 million in gross proceeds, which will be used for working capital and general corporate purposes, addressing immediate funding needs.

Next Steps

• The Company will file a resale registration statement covering the resale of the New Option Shares and Placement Agent Option Shares within 30 days after the Closing Date (January 12, 2026).
• The Company will use commercially reasonable efforts to cause the resale registration statement to be declared effective by the SEC within 60 days (or 90 days in certain circumstances) following January 9, 2026.
• The Company will maintain the listing or quotation of its Common Stock on its Trading Market and apply to list all New PIO Shares on such market.
• The Company will comply with restrictions on issuing certain Common Stock or Common Stock Equivalents for 45 days after the Closing Date.
• The Company will comply with prohibitions on Variable Rate Transactions for one year after the Closing Date.

Key Dates

Recommendation

The terms of this capital raise are highly dilutive and suggest a company in a precarious financial position. Inducing existing option holders to exercise at a drastically reduced price (from $9.00 to $2.575) and then issuing new options at 200% of the exercised shares, coupled with substantial placement agent fees, indicates a high cost of capital and a significant erosion of shareholder value. The immediate need for cash, obtained through such unfavorable terms, raises concerns about the Company's operational sustainability and future funding prospects. Investors should consider the significant dilution and the underlying reasons for such a costly capital raise.

Keywords

Arcadia Biosciences, RKDA, Preferred Investment Options, Capital Raise, Equity Financing, Dilution, SEC Filing, 8-K, Common Stock, Warrants, Private Placement